Rossari Biotech Reports Record Q4 Revenue of ₹685 Crore; Profit Jumps 34%

Rossari Biotech has reported its strongest financial quarter to date for Q4 FY26. The company announced consolidated revenue of ₹684.9 crore, marking an 18% year-on-year increase. Net profit after tax (PAT) saw a significant jump of 34% to ₹46.0 crore.

The company's performance was boosted by the recent addition of 15,000 MTPA ethoxylation capacity at its Dahej facility. This expansion brings its total installed ethoxylation capacity to 66,000 MTPA. Rossari also recommended a dividend of Re. 0.50 per share for FY26, indicating a focus on shareholder returns.

For the full fiscal year FY26, Rossari posted consolidated revenue of ₹2,396.4 crore (up 15% YoY) and PAT of ₹149.2 crore (up 9% YoY).

Driving Growth: Capacity Expansion and Innovation

The new 15,000 MTPA ethoxylation capacity, commissioned on March 31, 2026, is a key driver for meeting growing demand and enhancing production capabilities.

Furthering its innovation agenda, Rossari has established a new R&D facility in Koparkhairane, Navi Mumbai, and relocated its IIT Bombay facility. This move is expected to accelerate the development of new chemical solutions.

Strategic Focus and Future Outlook

Rossari Biotech has a history of strategically expanding its manufacturing and investing in research and development to meet market needs. This focus enables the creation of novel products for various industries.

The company's diversified business segments include Home, Personal Care & Performance Chemicals (HPPC), Industrial & Consumer Specialty Chemicals (ICSC), and Animal Health & Nutrition (AHN).

Key Changes and Shareholder Value

• Increased Production: The added ethoxylation capacity strengthens the company's manufacturing base for future growth.
• Innovation Pipeline: The new R&D center aims to speed up product development.
• Shareholder Returns: The recommended dividend offers direct value to investors.

Risks and Challenges

• Margin Pressures: Margins in Q4 FY26 were affected by raw material costs and a delay in passing these higher costs onto customers.
• Market Conditions: The company operates in a dynamic environment influenced by global events.

Peer Landscape

Rossari Biotech operates within the Indian specialty chemicals sector alongside major players like Aarti Industries, Vinati Organics, and Alkyl Amines Chemicals. While competitors may be larger, Rossari's recent capacity build-up and R&D investment are significant growth catalysts.

Key Performance Metrics (FY26)

• Q4 FY26 Revenue: ₹684.9 Cr (18% YoY growth)
• Q4 FY26 PAT: ₹46.0 Cr (34% YoY growth)
• Full Year FY26 Revenue: ₹2,396.4 Cr (15% YoY growth)
• Full Year FY26 PAT: ₹149.2 Cr (9% YoY growth)

What Investors Are Watching

• Margin Improvement: How effectively management can recover margins through pricing and product mix.
• Leveraging Capacity: The company's success in using its increased capacity and revenue to improve profitability.
• Capital Expenditure: Execution of previously adjusted capital spending plans.
• New Product Development: Progress on new products from the R&D pipeline.
• Dividend Policy: Future dividend plans.